A Phase 2, Multicenter Study to Evaluate the Efficacy and Safety Using Autologous Tumor Infiltrating Lymphocytes (LN-145) in Patients With Recurrent, Metastatic or Persistent Cervical Carcinoma

  • STATUS
    Recruiting
  • End date
    Dec 25, 2030
  • participants needed
    189
  • sponsor
    Iovance Biotherapeutics, Inc.
Updated on 25 October 2022
paclitaxel
cancer
carcinoma
squamous cell carcinoma
treatment regimen
chemoradiotherapy
carboplatin
adenosquamous carcinoma
pembrolizumab
bevacizumab
adenocarcinoma
immunomodulator
cervical carcinoma
cervical adenocarcinoma

Summary

Prospective, multicenter, single-arm, open label, interventional study evaluating adoptive cell therapy (ACT) with autologous tumor infiltrating lymphocytes (TIL) infusion (LN-145) followed by IL-2 after a non-myeloablative (NMA) lymphodepletion preparative regimen for the treatment of patients with recurrent, metastatic, or persistent cervical carcinoma

Description

LN-145 is an adoptive cell transfer therapy that utilizes an autologous TIL manufacturing process, as originally developed by the NCI, for the treatment of patients with recurrent, metastatic, or persistent cervical carcinoma. The cell transfer therapy used in this study involves patients receiving a NMA lymphocyte depleting preparative regimen, followed by infusion of autologous TIL followed by the administration of a regimen of IL-2.

Details
Condition Cervical Carcinoma
Treatment LN-145, LN-145 + pembrolizumab
Clinical Study IdentifierNCT03108495
SponsorIovance Biotherapeutics, Inc.
Last Modified on25 October 2022

Eligibility

Yes No Not Sure

Inclusion Criteria

To be eligible for the study, patients must meet ALL of the following criteria prior to
participation
Must be ≥ 18 years of age at the time of consent. Enrollment of patients > 70 years of
age may be allowed after consultation with the Medical Monitor
Must have recurrent, metastatic, or persistent squamous cell carcinoma (SCC)
adenosquamous carcinoma (ASC), or adenocarcinoma (AC) of the cervix that is not
amenable to curative treatment with surgery and/or radiation therapy
At least one resectable lesion (or aggregate of lesions resected) of a minimum 1.5 cm
in diameter post-resection to generate TIL; surgical removal with minimal morbidity
(defined as any procedure for which expected hospitalization is ≤ 3 days)
At least one measurable target lesion, as defined by RECIST v1.1
Cohort 1 and Cohort 2: Progression during or following at least one, but no more than
three, prior systemic chemotherapeutic treatments for recurrent, metastatic, or
persistent cervical carcinoma
A line of systemic therapy is defined as any chemotherapy or multiple-agent
chemotherapy regimen that was administered for recurrent, metastatic, or
persistent SCC, ASC, or AC of the cervix
A bevacizumab and chemotherapy combination is encouraged as a prior line of
treatment
Neither chemoradiation, nor chemotherapy in the neoadjuvant or adjuvant settings
are considered as a prior line of systemic therapy
Cohort 2: Must also have previously received treatment with a checkpoint inhibitor
(ie, PD-1, PD-L1]) in the setting of recurrent, metastatic, or persistent disease
either as monotherapy or in combination (eg, in combination with chemotherapy or
another immune agent)
Cohort 3 (United States only): Must have not received any therapies other than prior
chemoradiation or surgery for loco-regional disease
Any prior therapy directed at the malignant tumor, including chemotherapy
biologic/targeted agents, and immunologic agents must be discontinued at least 28 days
prior to tumor resection
Have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
Must have adequate organ function
Patient has no evidence of any active viral, bacterial, or fungal infection requiring
ongoing systemic treatment. Patients must be seronegative for the human
immunodeficiency virus (HIV). Patients with acute or chronic hepatitis infections may
be enrolled if the viral load by nucleic acid amplification test (NAAT) is
undetectable with/without active treatment
Patients of childbearing potential must be willing to take the appropriate precaution
to avoid pregnancy for the duration of the study and practice an approved, highly
effective method of birth control during treatment and for 12 months after receiving
the last protocol-related therapy
Prior to study Enrollment (tumor resection), patient must have documentation of
radiological disease progression after the most recent therapy

Exclusion Criteria

Patients who meet any of the following criteria are not eligible for participation in this
study
Patients who have received an organ allograft or prior cell transfer therapy except
for prior LN-145 therapy in the setting of re-treatment only
Patients who require ongoing systemic steroid therapy (> 10 mg/day of prednisone or
other steroid equivalent dose)
Patients who currently have prior therapy-related toxicities Grade > 1 according to
National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE)
v5.0; except for peripheral neuropathy, alopecia, or vitiligo prior to Enrollment
Patients who have a history of hypersensitivity to any component or excipient of
LN-145 or other study drugs
• NMA-LD preparative regimen (cyclophosphamide, mesna, and fludarabine)
Patients who have active systemic infections, coagulation disorders, or other active
major medical illness(es) of the cardiovascular, respiratory, or immune system
including evidence in the medical history of urinary tract obstruction, a positive
cardiac stress test, myocardial infarction, cardiac arrhythmia, obstructive or
restrictive pulmonary disease, or other conditions that in the opinion of the
Investigator would increase the risk of participation
Patients with symptomatic and/or untreated brain metastases (of any size and any
number)
• Patients with definitively treated brain metastases may be considered for
Enrollment, and must be stable for ≥ 14 days prior to beginning the NMA-LD preparative
regimen
Patients who have any form of primary immunodeficiency (such as severe combined
immunodeficiency [SCID] or acquired immunodeficiency syndrome [AIDS])
Patients who have a diagnosis of end-stage renal disorder requiring hemodialysis
Patients who have a left ventricular ejection fraction (LVEF) < 45% or who are New
York Heart Association (NYHA) Class 2 or higher
Patients who have a documented forced expiratory volume in 1 second (FEV1) of ≤ 60%
Patients who have had another primary malignancy within the previous 3 years (except
for curatively treated localized malignancy that has not required treatment for > 1
year, and in the judgement of the Investigator, does not pose a significant risk of
recurrence including, but not limited to, non-melanoma skin cancer or bladder cancer)
Patients who are of the following protected classes will be excluded, including
Pregnant, parturient, or breastfeeding women
Persons who are hospitalized without consent or those deprived of liberty because
of a judiciary or administrative decision
Patients with a legal protection measure or a person who cannot express his/her
consent
Patients in emergency situations who cannot consent to the study
(tumor resection)
Patients who have received a live or attenuated vaccine within 28 days prior to
beginning the NMA-LD preparative regimen
Patients whose cancer requires immediate attention or who would otherwise suffer a
disadvantage by participating in this study
Cohort 1 and Cohort 3: Patients who have received prior treatment with immunotherapy
(eg, PD-1, PD-L1, or anti-cytotoxic T lymphocyte-associated antigen-4 [CTLA-4]
antibodies)
Patients who have Grade ≥ 2 hemorrhage within 14 days prior to Enrollment (tumor
resection)
Cohort 3: Patients may not have active or prior documented autoimmune or inflammatory
disorders (including pneumonitis, inflammatory bowel disease [eg, colitis or Crohn's
disease], diverticulitis [with the exception of diverticulosis], systemic lupus
erythematosus, sarcoidosis syndrome, or Wegener syndrome [granulomatosis with
polyangiitis, Graves' disease, rheumatoid arthritis, hypophysitis, uveitis, etc.])
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note